Angina and Non-Obstructive Coronary Artery (ANOCA) Patients with Coronary Vasomotor Disorders

Sarena La1,2,3, Rosanna Tavella1,2,3, Jing Wu1

  • 1School of Medicine, Faculty of Health Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.

Life (Basel, Switzerland)
|November 25, 2023
PubMed

Insights

Diagnosing coronary vasomotor disorders in Angina and Non-Obstructive Coronary Artery (ANOCA) patients improves symptom management. Identifying these conditions leads to more emergency visits and readmissions for chest pain, highlighting the need for personalized care.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Diagnostic Imaging

Background:

  • Angina and Non-Obstructive Coronary Artery (ANOCA) patients often receive a diagnosis of unspecified chest pain.
  • Functional coronary angiography can identify coronary vasomotor disorders, but their impact on ANOCA patient outcomes is unclear.

Purpose of the Study:

  • To compare the outcomes of ANOCA patients diagnosed with coronary vasomotor disorders versus those discharged with unspecified chest pain.

Main Methods:

  • Analysis of the CADOSA registry (2012-2018) including 7555 symptomatic patients undergoing elective angiography.
  • Identification of 30% ANOCA patients (stenosis <50%), with 9% diagnosed with coronary vasomotor disorders.

Main Results:

  • Patients with coronary vasomotor disorders were younger and had similar female prevalence.
  • While all-cause mortality was similar, those with diagnosed disorders had significantly higher rates of emergency department visits (39% vs 15%) and readmissions (30% vs 10%) for chest pain within 3 years.

Conclusions:

  • Diagnosing coronary vasomotor disorders in ANOCA patients is crucial for personalized management.
  • Despite similar mortality, identified disorders correlate with increased healthcare utilization for chest pain symptoms.

Related Concept Videos

Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
598
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
533
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
537
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436